Skip to main content

Table 4 Incremental cost-effectiveness results

From: Effectiveness and costs of non-invasive foetal RHD genotyping in rhesus-D negative mothers: a French multicentric two-arm study of 850 women

Intervention n Average cost (€) Performance a (%) ∆ Cost (€) ∆ Performancea (%) ICER ∆ Cost / ∆ Performancea
Based on costs related to RHD status (tests, anti-D injections and visits)
 Usual care 452 64%    
 RHD genotyping 591 88% 139 24% 578
  1. a Performance is defined as the percentage of RHD negative women receiving appropriate management